An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients: a Phase II Study of the Intergroupe Francophone du Myélome "IFM 2018-04"
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2019
Price : $35 *
At a glance
- Drugs Carfilzomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 30 Jul 2019 Planned End Date changed from 2 Nov 2026 to 2 Nov 2027.
- 30 Jul 2019 Planned primary completion date changed from 2 Feb 2020 to 2 Feb 2021.
- 30 Jul 2019 Status changed from not yet recruiting to recruiting.